[The role of oncology nurses in treatment outcomes. What can we do for the patients' compliance treated with intravenous zoledronic acid?].
Patients with cancer and bone metastasis usually need to be treated with bisphosphonates to reduce or delay skeletal complications (pathologic fracture, hypercalcemia, surgery or radiotherapy). The nurses can provide important education to patients, support and encourage use of bisphosphonates throughout therapy. Literatures, training, congress reports provide useful information about bisphosphonate therapy, side effects, adverse events etc. However, patients need more information to support them during courses. To optimize the care, nurses can monitor pain scores, changes in mobility, adverse events, creating clearance levels. A useful tool for recording these parameters is a patients-diary. The nurse should fill out the diary at each patients visit and compare it to the baseline information before treatment. At the same time they can get some information from the patient's performance (adequate hydration, dental hygiene). Nurses play an important role in the care of patients during bisphosphonate therapy and in supporting patients to continue treatment to preserve their functional independence.
Zatkóné Puskás
Gabriella
G
Fovárosi Onkormányzat Uzsoki utcai Kórháza Onkoradiológiai Központ, Kemoterápiás Ambulancia 1145 Budapest Uzsoki utca 29-41. zatko.gabi@uzsoki.hu
D000328:Adult; D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D024802:Nurse's Role; D009859:Oncology Nursing / Q000379:methods*; D010349:Patient Compliance; D010353:Patient Education as Topic / Q000379:methods; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid